---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-039326"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2021-07-30T23:59:59+00:00"
generated_at: "2026-06-30T00:37:57.904694+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q2 revenue $826M (+30% reported, +25% organic); raises FY 2021 guidance

## Summary
- EPS of $2.34, up 36% as reported and 33% comparable basis.
- CAG Diagnostics recurring revenue grew 30% reported, 26% organic.
- 2021 revenue guidance raised to $3,170M-$3,205M (17%-18.5% reported growth).
- 2021 EPS outlook raised to $8.20-$8.36; operating margin forecast 28.6%-29.1%.
- U.S. same-store clinical visit growth 13% in Q2; premium instrument placements doubled YoY.

## SEC filing metadata
- accession: 0001564590-21-039326
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2021-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000156459021039326/0001564590-21-039326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000156459021039326/idxx-8k_20210730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-039326
- JSON: https://secwatch.observer/filing/0001564590-21-039326.json
- Plain text: https://secwatch.observer/filing/0001564590-21-039326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.